Study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 diabetes or obesity
https://newsroom.clevelandclinic.org/2024/09/13/cleveland-clinic-study-identifies-key-factors-that-can-impact-long-term-weight-loss-in-patients-with-obesity-who-were-prescribed-glp-1-ra-medications
2 Comments
>Overall, 37.4% of patients receiving semaglutide for obesity achieved 10% or more body weight reduction compared to 16.6% of patients receiving semaglutide for type 2 diabetes. In comparison, 14.5% of those receiving liraglutide for obesity achieved 10% or more body weight reduction versus 9.3% of those receiving liraglutide for type 2 diabetes.
>
>Among patients who persisted with their medication one year after their initial prescriptions, the proportion who achieved 10% or more weight reduction was 61% with semaglutide for obesity, 23.1% with semaglutide for type 2 diabetes, 28.6% with liraglutide for obesity, and 12.3% with liraglutide for type 2 diabetes.
>
>Based on the study’s multivariable analysis that accounted for relevant socio-demographic and clinical variables, the following factors were associated with higher odds of achieving 10% or more weight reduction one year after the initial prescriptions:
>
>- Patients who received semaglutide versus liraglutide
>
>- A high maintenance dose of the medication versus low
>
>- Obesity as a treatment indication versus type 2 diabetes
>
>- Patients who persisted with the medication within the first year or had between 90-275 days of medication coverage versus less than 90 days of medication coverage
>
>- Patients who had higher initial BMI
>
>- Patients who were female versus male
Paper: [One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice | Diabetes and Endocrinology | JAMA Network Open | JAMA Network](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823644)
Interesting data. I like the way the tackled the problem. The issue is that the results of the study are sort of “no brainers” for how medications in general work.
1) More bioselective med
2) higher dose
3) obesity as indication – have higher BMI
4) adhered to the medication
5) had higher BMI
The female > male predominance is the take home point for me. Which is great for setting expectations about the med.